ID,Responder,therapy_start,Abnahmedatum,Baseline,TRIM_PDL1_Expression,therapy_at_blood_draw,ECOG,breslow_thickness_mm,subtype,localization,sex,Alter,Hirnmetastase,adjuvant_IFN,befallen_Organe,Eosinophile,CRP,LDH,S100,BRAF,nras,Stadium,Vorbehandlung
ID,Responder,therapy_start,Abnahmedatum,Baseline,TRIM_PDL1_Expression,therapy_at_blood_draw,ECOG,breslow_thickness_mm,subtype,localization,sex,Alter,brainMet,adjuvant_IFN,organsInvolved,Eosinophile,CRP,LDH,S100,BRAF,nras,Stadium,Vorbehandlung

1,,NA,NA,NA,,,,,,,,,,,,,,,,,,,
2,,NA,NA,NA,,,,,,,,,,,,,,,,,,,
3,ja,Feb 15,31.03.2016,nein,,Pembrolizumab,0,NA,cutanes Melanom,trunk,m,69,,nein,1,4.3,2.3,159,0.04,neg.,,IV,"2012 dendritische T-Zell-Therapie, 10-12/15 4 Zyklen Ipilimumab "
4,nein,Jan 14,31.03.2016,nein,,Dabrafenib/Trametinib,0,8.0 mm,cutanes Melanom,head / neck,m,79,,nein,3,3.3,18.9,231,0.09,pos.,,IV,"2-6/13 Zelboraf, 1-7/14 9 Zyklen Keytruda, 8-10/14 4 Zyklen Ipi, 11/14-5/15 Tafinlar und Mekinist, seit 6/15 - lfd. Tafinlar 75 mg 1-0-1 und 11 Zyklen DTIC"
5,ja,Sep 15,31.03.2016,nein,,Pembrolizumab,0,6.0 mm,cutanes Melanom,acral,m,73,,ja,2,3.1,0.8,290,,neg.,,IV,"11/02-07/04 adj. Chemo mit DTIC (21 Zyklen), 10/04-10/05 Hochdosis Inteferontherapie, seit 10/15 XGEVIA, seit 09/15 6 Zyklen Keytruda"
6,ja,Mrz 15,31.03.2016,nein,,Nivolumab,1,3.0 mm,cutanes Melanom,head / neck,w,82,,nein,3,9.8,5.5,174,0.11,neg.,,IIIC,"11/12-01/13 4 Zyklen Ipilimimab 3mg/KgKG,12/13-02/14 4 Zyklen Re- Induktion Ipilimumab 3mg/KgKG, seit 03/15 24 Zyklen Anti PD-I (BMS-Studie)"

7,ja,Mrz 14,19.04.2016,nein,,Nivolumab,0,1.65 mm,cutanes Melanom,trunk,m,63,,ja,4,1.1,2.7,239,0.38,neg.,,IV,"03/07-09/08 adj. IFN s.c.,04/13 1 Zyklus DTIC 1000mg/m�, 06-07/13 3 Zyklen Ipilimumab, 07/13 Temodal 420 mg �ber 5 Tg., 03/14 -04/16 52 Zyklen Nivolumab in BMS Studie"

7,ja,Mrz 14,19.04.2016,nein,,Nivolumab,0,1.65 mm,cutanes Melanom,trunk,m,63,,ja,4,1.1,2.7,239,0.38,neg.,,IV,"03/07-09/08 adj. IFN s.c.,04/13 1 Zyklus DTIC 1000mg/m², 06-07/13 3 Zyklen Ipilimumab, 07/13 Temodal 420 mg über 5 Tg., 03/14 -04/16 52 Zyklen Nivolumab in BMS Studie"

8,ja,Jan 16,31.03.2016,nein,,Pembrolizumab,0,NA,NA,,m,49,,nein,3,4.6,4.7,233,0.06,pos.,,,"05/14-10/14 BRAF und MEK- Inhibitor (Tafinlar+Mekinest),10-12/14 4 Zyklen Ipilimumab, seit 01/16 3 Zyklen Keytruda 2mg/KgKG"
9,nein,Mrz 15,31.03.2016,nein,,Nivolumab,0,6.5 mm,cutanes Melanom,extremities,w,44,,ja,2,1.6,0.3,162,,pos.,,IIIC,"07/08-06/09 Hochdosis IFN Intron-A, 11/10 8 Zyklen IL2, 06-09/13 4 Zyklen Ipi, 02-03/14 8 Zyklen IL2, 03/15-04/16 30xNivolumab,07/15 7x IL2,"
10,ja,Jan 15,22.04.2016,nein,,Pembrolizumab,0,1.0 mm,cutanes Melanom,extremities,w,63,ja,,2,2,2.3,179,0.05,neg.,pos,IV,"07-08/14 3 Zyklen IPI, 10/14 3x Remicade, 01/15-lfd Zyklen Keytruda"
11,nein,keine Therapie,29.03.2016,NA,,Ipilimumab,1,9.0 mm,cutanes Melanom,trunk,w,66,,nein,3,0.1,3,256,,neg.,,IV,"01-03/16 4 Zyklen Keytruda, seit 03/16 Ipi (3mg(KgKG)"
12,nein,Sep 16,01.04.2016,ja,,Dabrafenib/Trametinib,0,2.25 mm,cutanes Melanom,extremities,m,33,,ja,,0.5,2.1,238,0.08,pos.,,IV,"06/04-06/05 Hochdosis IFN,09/07-02/09+05/11-09/13 Peptidvakzinierung, 05/09-01/10 8 Zyklen DTIC, Carmujstin und Cisplatin,01-01/14 4x Ipilimumab,01-05/15 Tafinlar und Mekinist, seit 02/16 Re- Start Tafinlar und Mekinist"

13,nein,Aug 15,01.04.2016,nein,,Pembrolizumab,1,NA,cutanes Melanom,trunk,m,80,,,3,6.5,6.5,252,0.14,neg.,,IV,"seit 09/15 8 Zyklen Pembrolizumab 2mg/KgKG, 20.04.16:Temodal 140 mg f�r 5 Tage"

13,nein,Aug 15,01.04.2016,nein,,Pembrolizumab,1,NA,cutanes Melanom,trunk,m,80,,,3,6.5,6.5,252,0.14,neg.,,IV,"seit 09/15 8 Zyklen Pembrolizumab 2mg/KgKG, 20.04.16:Temodal 140 mg für 5 Tage"

14,nein,keine Therapie,01.04.2016,NA,,Elektrochemotherapie,1,NA,cutanes Melanom,head / neck,m,69,nein,nein,2,2,5,308,0.23,neg.,,IV,"09-11/15 4 Zyklen Keytruda, 11/15-02/16 4 Zyklen Ipilimumab, darunter Progeress, geplant Mekinist Monotherapie"
15,nein,Jun 14,01.04.2016,nein,+,Pembrolizumab,0,1.45 mm,cutanes Melanom,,w,44,ja,ja,3,4.9,3.5,204,0.07,pos.,,IV,"8-10/13 Zelboraf, 10-12/13 4 Zyklen Ipi, 1-6/14 Tafinlar und Mekinist,  6/14-lfd.28 Zyklen Pembro"
16,nein,Mrz 16,01.04.2016,ja,,Pembrolizumab,0,5.6 mm,cutanes Melanom,trunk,m,75,,nein,3,1.2,2.4,210,0.77,pos.,,IV,"06/15 Tafinlar 75 2-0-2 und Mekinist 2mg 1xtgl., seit 03/16 2 Zyklen keytruda"
17,NA,keine Therapie,05.04.2016,NA,,Interferon,0,0.95 mm,cutanes Melanom,trunk,w,62,nein,ja,1,1.1,1.6,345,0.06,neg,,IIIC,04/16 Start mit IFN 3x3 MIO s.c. /Woche
18,NA,keine Therapie,05.04.2016,NA,++,Placebo i.R. einer Studie,0,1.7 mm,cutanes Melanom,acral,w,52, ,nein,,2.9,0.8,166,0.06,pos.,,IIIB,02-03/16 2 Zyklen EORCT Studie Pembro/ Placebo lfd
19,ja,Feb 14,05.04.2016,nein,,MEK-Inhibitor,1,8.0 mm,cutanes Melanom,trunk,w,74,nein,ja,3,2.2,1.2,276,0.11,neg.,,IV,"02-05/14 7x Anti PD-1 880mg, 06/14-05/16  MEK- Inhibitor (NEMO-St.) mehrmals Pause wg. NW, "
20,nein,Sep 14,07.04.2016,nein,,Pembrolizumab,0,1.5 mm,cutanes Melanom,extremities,w,76,nein,nein,2,2.4,0.6,185,0.04,pos.,,IV,"05-07/14 4 Zyklen Ipilimimab, seit 09/14 27 Zyklen Keytruda"
21,NA,keine Therapie,07.04.2016,NA,,-,0,6.48 mm,cutanes Melanom,extremities,m,59,nein,ja,1,0.4,1,190,0.19,pos.,,IIIC,"08/13-04/14 IFN 3x5 Mio IE, 04-07/15 12 Zyklen IL-2"
22,ja,Jan 16,07.04.2016,nein,,Pembrolizumab,1,NA,Schleimhautmelanom,head / neck,w,76,ja,,3,0.3,0.2,141,,neg.,,IV,"seit 01/16 Keytruda 2mg/kgKG, bisher 3 Zyklen"
23,ja,Feb 16,07.04.2016,nein,,Pembrolizumab,0,4.2 mm,cutanes Melanom,acral,m,72,nein,nein,1,4.9,0.6,228,0.04,neg.,,IIC/IV,"02-03/16 2 Zyklen Keytruda (2mg/KgKG)lfd,"
24,nein,Okt 15,07.04.2016,nein,,Pembrolizumab,2,2.8 mm,cutanes Melanom,extremities,m,87,ja,nein,3,3,1.6,207,0.09,pos.,,IV,10/15-03/16 8 Zyklen Keytruda lfd.
25,NA,Jun 16,07.04.2016,ja,,Placebo i.R. einer Studie,0,NA,NA,,w,69,nein,nein,3,1.5,2,190,0.15,pos.,,IV,"seit 04/11 Beginn mit MEK Inhibitor 2mg/d p.os,, aktuell Immuned-Studie"
26,nein,Jan 16,12.04.2016,nein,,Pembrolizumab,1,22.0 mm,cutanes Melanom,trunk,m,77,nein,nein,3,0.3,71.3,478,0.56,neg.,,IV,seit 01/16 Keytruda 2mg/KgKG alle 3 Wochen (bisher 4 Zyklen)
27,nein,Jan 16,12.04.2016,nein,,Pembrolizumab,0,2.9 mm,cutanes Melanom,trunk,w,45,nein,nein,3,1.8,11.6,218,0.02,pos.,,IV,"08/15 Tafinlar 75 2-0-2+ MEK 2mg 1-0-0, seit 01/16 4 Zyklen Keytruda lfd."
28,nein,Jan 16,12.04.2016,nein,-,Ipilimumab,1,28.0 mm,cutanes Melanom,acral,m,84,nein,nein,1,1.3,285,393,2.42,neg.,,IIIC,"02-03/15 8x IL-2 s.c., 11/15-01/16 5x Opdivo, siet 01/16 3x Yervoy (Ipilimumab) 3mg/KgKG"
29,nein,Mai 16,12.04.2016,ja,,Pembrolizumab,1,0.9 mm,cutanes Melanom,trunk,m,76,nein,nein,3,3,6.6,233,0.06,neg.,,IIIC,11.05.16 Pembrolizumab 2mg/Kg KG
30,nein,Apr 17,14.04.2016,ja,,Dabrafenib/Trametinib,0,4.5 mm,cutanes Melanom,extremities,w,60,ja,ja,3,0.2,3.6,233,0.1,pos.,,IV,"04/98-03/00 low-dose IFN, 08/03-05/04 3 Zyklen IFN Hochdosis, 05-07/15 4 Zyklen Ipi, 08/15 2 Zyklen Remicade, 02/16 Beginn Tafinlar 75mg(2-0-2)+ Mekinist 2 mg(1xtgl.)lfd."
31,ja,Aug 15,14.04.2016,nein,++,-,0,1.6 mm,cutanes Melanom,extremities,w,73,,,2,4.1,6.5,213,0.08,neg.,,IV,"03-04/15 3 Zyklen Ipi (Colitis), 05-06/15 2 Zyklen Remicade, 08-12/15 7 Zyklen Keytruda (Colitis), wait and see"
32,ja,Jul 16,30.08.2016,ja,-,-,0,2.0 mm,cutanes Melanom,head / neck,w,, ,,,0.6,13.1,185,0.09,pos.,,IIIC,
33,ja,Jun 15,14.04.2016,nein,,Pembrolizumab,0,NA,cutanes Melanom,NA,m,74,nein,nein,1,0.8,3.5,188,0.03,neg.,,IV,"03-05/15 4 Zyklen Ipi, 06/15-03/16 15 Zyklen Keytruda lfd.,"

34,ja,Okt 13,26.04.2016,nein,,Nivolumab,1,3.2 mm,cutanes Melanom,extremities,w,78,nein,ja,3,1.6,4.6,153,0.09,neg,,IV,"12/11 adj. IFN Therapie 3x3 Mio IE s.c., 08/12 2 Zyklen DTIC 1000mg/m�KOF,12/12 4 Zyklen Ipilimumab,seit  10/13 60 Zyklen PD-1 Therapie"

34,ja,Okt 13,26.04.2016,nein,,Nivolumab,1,3.2 mm,cutanes Melanom,extremities,w,78,nein,ja,3,1.6,4.6,153,0.09,neg,,IV,"12/11 adj. IFN Therapie 3x3 Mio IE s.c., 08/12 2 Zyklen DTIC 1000mg/m²KOF,12/12 4 Zyklen Ipilimumab,seit  10/13 60 Zyklen PD-1 Therapie"

35,ja,Apr 16,26.04.2016,ja,,Ipilimumab+Nivolumab,0,8.0 mm,cutanes Melanom,extremities,m,38,nein,nein,3,6.8,4,168,0.05,neg.,,IIIC,seit 26.04.16 3 Zyklen Immuned-Studie 
36,ja,Jun 15,26.04.2016,nein,,Pembrolizumab,2,NA,NA,NA,m,92,nein,nein,2,2,7.8,185,0.14,neg.,,IV,seit 06/15 14 Zyklen Keytruda
37,nein,Aug 16,28.04.2016,ja,,Interleukin,0,1.3 mm,cutanes Melanom,head / neck,m,45,nein,ja,1,1.7,5.5,178,0.09,neg.,,IIIC,
38,ja,Jul 15,28.04.2016,nein,,Nivolumab,1,5.0 mm,cutanes Melanom,extremities,m,77,ja,nein,2,5,0.4,160,0.07,pos.,,IV,seit 07/15 21 Zyklen Opdivo
39,nein,Aug 16,28.04.2016,ja,,Encorafenib/Binimetinib,0,12.0 mm,cutanes Melanom,acral,m,36,nein,nein,3,2.3,3.3,203,0.04,pos.,,IV,"seit 14.07.15 Columbus Studie: LGX 300+MEK Inh. 45 mg., 15.11.15 Pause wg. Phlegmone, Re-Start am 28.11.15, Zyklus 11"
40,NA,keine Therapie,28.04.2016,NA,,-,0,9.0 mm,cutanes Melanom,head / neck,w,50,nein,ja,1,2,1.2,136,0.1,pos.,,IIIC,
41,nein,Mrz 16,03.05.2016,nein,,Pembrolizumab,2,1.4 mm,cutanes Melanom,trunk,m,52,nein,nein,2,2.2,10.2,399,,pos.,,IV,seit 3/16 2 Zyklen Keytruda
42,NA,keine Therapie,03.05.2016,NA,,-,0,NA,cutanes Melanom,extremities,w,76,,ja,3,1.4,1.3,178,0.07,NA,,IIIC,
43,ja,Jun 15,03.05.2016,nein,,Pembrolizumab,1,9.0 mm,Schleimhautmelanom,vulva,w,74,nein,nein,2,3.5,0.6,177,0.1,neg.,,IV,"10-12/14 3 Zyklen Ipilimumab, seit 06/15 Keytruda bisher 15 Zyklen "
44,ja,Jun 17,10.05.2016,ja,,-,0,NA,Schleimhautmelanom,anal,w,76,nein,nein,0,2.9,0.6,182,0.05,neg.,,,
45,NA,Nov 13,10.05.2016,nein,,Dabrafenib/Trametinib,0,23.0 mm,cutanes Melanom,trunk,m,61,nein,,2,0.8,6.3,213,0.05,pos.,,IV,"11/13-11/14 23 Zyklen Anti PD-I/ Ipilimumab in BMS Studie. 04/15 Columbus Studie Mono Lux(BRAF-Inh.)300-200-100mg, 11/15 Tafinlar+Mekinist"
46,nein,Mai 16,12.05.2016,ja,,Ipilimumab+Nivolumab,2,NA,cutanes Melanom,extremities,m,36,nein,nein,1,2.7,1.3,188,0.78,neg.,,IV,seit 18.05.16 Immuned-Studie Opdivo 1mg/kgKG+ Ipilimumab 3mg/kg KG
47,ja,Feb 16,12.05.2016,nein,,Pembrolizumab,0,4.0 mm,cutanes Melanom,trunk,m,42,ja,ja,2,5.2,10.4,157,0.03,pos.,,IV,"11/09-11/10 adj. Immunth. Mit Hochdosis Interferon, 01/15 Beginn mit Yervoy i.v. insg. 4 Zyklen, 04/15 Beginn Dabrafenib 150 2xtgl., 09/15 adoptive T- Zell Transfer in Manchester, seit 02/16 6 Zyklen Opdivo"
48,ja,Feb 14,12.05.2016,nein,,PD-1 bis 05/15 mit Vollremission,0,NA,cutanes Melanom,,m,,,,,1,1.2,195,0.03,pos.,,IV,
49,ja,Sep 14,12.05.2016,nein,,Pembrolizumab,1,2.1 mm,cutanes Melanom,head / neck,m,50,ja,ja,2,10,1,166,0.04,pos.,,IV,"IFN, 07/13 Temodal (abbruch), 08-10/13 4x Ipilimumab,11/13 Tafinlar 150mg 1-0-1/d, 04/14  Mekinist seit 09/14 Anti-PD-I-EAP Programm bisher 28 Zyklen"
50,ja,Nov 15,12.05.2016,nein,,Pembrolizumab,1,2.3 mm,cutanes Melanom,trunk,m,85,ja,nein,3,1.5,0.6,192,0.56,neg.,,IV,seit 11/15 9 Zyklen Keytruda
51,nein,Jul 14,12.05.2016,nein,,Dabrafenib/Trametinib,0,3.2 mm,cutanes Melanom,extremities,w,55,ja,,3,2.4,25.2,290,0.15,pos.,,IV,"05-10/13 Zellboraf,10-12/13 4x Ipilimumab,07-10/14 5 Zyklen Anti-PD-I (EAP Programm).11/14 Beginn Tafinular 150mg 2xtgl,12/14 Beginn MEK 2mg 1xtgl., reduziert 07/15 75 2xtgl"
52,ja,Aug 15,17.05.2016,nein,,Pembrolizumab,0,4.5 mm,cutanes Melanom,trunk,m,72,nein,ja,2,0.6,2,199,0.26,neg.,,IV,"01-05/12 Low dose IFN, 05-07/15 4 Zyklen Ipilimimab,seit 08/15 12 Zyklen Keytruda 2mg/kgKG"

53,ja,Feb 15,17.05.2016,nein,++,Nivolumab,0,4.5 mm,cutanes Melanom,trunk,w,36,nein,ja,2,1.2,3.3,128,0.05,neg.,,IV,"06-07/13 2x DTIC 1000mg/M�KOF, 09-11/13 4x Ipilimumab, seit 02/15 Studie BMS NIVO 210mg (bisher 33 Zyklen)"
54,nein,Nov 13,17.05.2016,nein,,Encorafenib,0,0.6 mm,cutanes Melanom,trunk,m,47,nein,,2,3.1,5.4,153,0.02,pos.,,IV,"11/13-04/14  PD-1 vs. Ipi. Vs. Anti PD1+ Ipi in BMS Studie. Studie insg. 13 mal., 05/14 Beginn  BRAF Inhibitor in Columbusstudie 300(200-100)mg, bisher 26 Zyklen"
55,NA,keine Therapie,19.05.2016,NA,,-,2,1.1 mm,cutanes Melanom,trunk,m,74,nein,nein,3,1.4,4.6,127,0.03,pos.,,IV,07/10-03/11 9 zyklen DTIC 1000mg/m�KOF
56,NA,keine Therapie,19.05.2016,NA,,Dabrafenib/Trametinib,1,2.25 mm,cutanes Melanom,extremities,w,67,ja,,4,1,12.9,230,0.1,pos.,,IV,seit 11/15 Tafinlar und Mekinest
57,NA,keine Therapie,19.05.2016,NA,,Ipilimumab 2013 mit complete response,0,4.4 mm,cutanes Melanom,trunk,w,55,nein,ja,2,0,1.5,215,0.06,neg.,,IV,"06-07/13 2 Zyklen DTIC, 08-10/13 4 Zyklen Ipilimumab"
58,ja,Nov 15,19.05.2016,nein,,Pembrolizumab,1,2.25 mm,cutanes Melanom,acral,m,86,nein,nein,1,6.3,3.6,184,0.1,pos.,,IIIC,seit 11/15  9 Zyklen Anti-PD-1- Therapie
59,nein,Aug 15,26.05.2016,nein,-,Temozolomid,1,3.0 mm,cutanes Melanom,head / neck,w,79,ja,ja,3,2.9,16.9,237,0.13,neg.,,IV,"07-08/14 Inteferon Therapie s.c. 3x/woche,04-07/15 4 Zyklen Ipilimumab, 08/15-02/16 10 Zyklen Keytruda, seit 03/16 3 Zyklen Temodal 360 mg jeweils �ber 5 Tage"

53,ja,Feb 15,17.05.2016,nein,++,Nivolumab,0,4.5 mm,cutanes Melanom,trunk,w,36,nein,ja,2,1.2,3.3,128,0.05,neg.,,IV,"06-07/13 2x DTIC 1000mg/M²KOF, 09-11/13 4x Ipilimumab, seit 02/15 Studie BMS NIVO 210mg (bisher 33 Zyklen)"
54,nein,Nov 13,17.05.2016,nein,,Encorafenib,0,0.6 mm,cutanes Melanom,trunk,m,47,nein,,2,3.1,5.4,153,0.02,pos.,,IV,"11/13-04/14  PD-1 vs. Ipi. Vs. Anti PD1+ Ipi in BMS Studie. Studie insg. 13 mal., 05/14 Beginn  BRAF Inhibitor in Columbusstudie 300(200-100)mg, bisher 26 Zyklen"
55,NA,keine Therapie,19.05.2016,NA,,-,2,1.1 mm,cutanes Melanom,trunk,m,74,nein,nein,3,1.4,4.6,127,0.03,pos.,,IV,07/10-03/11 9 zyklen DTIC 1000mg/m²KOF
56,NA,keine Therapie,19.05.2016,NA,,Dabrafenib/Trametinib,1,2.25 mm,cutanes Melanom,extremities,w,67,ja,,4,1,12.9,230,0.1,pos.,,IV,seit 11/15 Tafinlar und Mekinest
57,NA,keine Therapie,19.05.2016,NA,,Ipilimumab 2013 mit complete response,0,4.4 mm,cutanes Melanom,trunk,w,55,nein,ja,2,0,1.5,215,0.06,neg.,,IV,"06-07/13 2 Zyklen DTIC, 08-10/13 4 Zyklen Ipilimumab"
58,ja,Nov 15,19.05.2016,nein,,Pembrolizumab,1,2.25 mm,cutanes Melanom,acral,m,86,nein,nein,1,6.3,3.6,184,0.1,pos.,,IIIC,seit 11/15  9 Zyklen Anti-PD-1- Therapie
59,nein,Aug 15,26.05.2016,nein,-,Temozolomid,1,3.0 mm,cutanes Melanom,head / neck,w,79,ja,ja,3,2.9,16.9,237,0.13,neg.,,IV,"07-08/14 Inteferon Therapie s.c. 3x/woche,04-07/15 4 Zyklen Ipilimumab, 08/15-02/16 10 Zyklen Keytruda, seit 03/16 3 Zyklen Temodal 360 mg jeweils über 5 Tage"

60,NA,keine Therapie,26.06.2016,NA,,-,1,1.5 mm,cutanes Melanom,head / neck,w,75,,ja,1,12.1,12.8,217,0.08,NA,,IIIC,seit 9.05.16 5 Zyklen IL-2 Unterspritzung von 9 MIO IE.
61,nein,Aug 17,26.05.2016,ja,,-,0,1.3 mm,cutanes Melanom,extremities,w,49,ja,,1,2.7,2.6,146,0.1,pos.,,IV,keine in den Akten
62,NA,keine Therapie,14.06.2016,NA,,-,0,2.0 mm,cutanes Melanom,acral,w,59,,ja,1,1.4,0.4,189,0.1,NA,,IIIC,09-10/12 radiatio
63,nein,Jun 16,16.06.2016,ja,,Pembrolizumab,1,5.7 mm,cutanes Melanom,head / neck,m,,,,,1.6,2.5,189,0.08,pos.,,IV,
64,NA,keine Therapie,16.06.2016,NA,,-,0,1.7 mm,cutanes Melanom,trunk,m,80,nein,nein,1,5.9,0.3,294,0.06,NA,pos,IIIC,"03/16 Elektrochemotherapie Brustwand, 04-05/16 postop Radiatio bis 45Gy"
65,nein,keine Therapie,16.06.2016,NA,,Roferon,2,NA,NA,,w,,,,,0.4,0.6,213,0.07,neg.,,IIIC,
66,ja,Nov 16,16.06.2016,ja,,-,0,2.5 mm,cutanes Melanom,extremities,m,51,nein,ja,2,12.5,0.5,177,0.04,neg.,,IV,"16.06.16 Pat kommt in Immuned- Studie, Dosierung nicht in  Akte"
67,nein,Jan 16,16.06.2016,nein,,Pembrolizumab,1,NA,NA,,m,,,,,0.3,15.2,288,0.07,neg.,,IV,
68,nein,Aug 16,21.06.2016,ja,,Ipilimumab+Nivolumab,2,8.0 mm,cutanes Melanom,acral,w,,,,,2.4,10.9,200,0.15,pos.,,IV,
69,nein,Jun 16,23.06.2016,ja,,Ipilimumab+Nivolumab,1,5.5 mm,cutanes Melanom,trunk,m,67,nein,ja,4,1.1,12.7,228,0.1,neg.,,IV,"03/09-09/13 23 Zyklen DTIC ,09-11/13 4 Zyklen Ipilimimab 3mg/kgKG, 06/16 Start mit Immunkombi Ipilimimab 3mg/kgKG+ Nivolumab 1mg/kgKG"
70,nein,Okt 15,23.06.2016,nein,,Dacarbazin,2,9.0 mm,Schleimhautmelanom,anal,w,,,,,2.1,10.5,333,0.58,neg.,,IV,
71,nein,Okt 16,23.06.2016,ja,,Ipilimumab+Nivolumab,1,11.0 mm,cutanes Melanom,trunk,m,83,nein,,4,0.5,1.9,191,0.37,pos.,,IV,"02/16 Neck dissekt., 03-04/16 adj. Radiotherapie, Beginn Mekinist und Tafinular geplant (Einschluss Combi-R- Studie)"
72,NA,keine Therapie,05.07.2016,NA,,-,0,0.85 mm,cutanes Melanom,extremities,m,60,nein,nein,1,1.6,1.8,181,0.06,pos.,,IIIC,"11/13-04/14 Vemurafenib in unterschiedl. Dosierungen extern, Abbruch nach Resektion LK Filiae"
73,nein,Nov 16,05.07.2016,ja,,-,0,1.4 mm,cutanes Melanom,head / neck,m,81,ja,nein,1,0.2,0.3,310,0.1,neg.,,IV,"11/14-01/15 4 Zyklen Ipilimumab 3mg/kgKG, Bestrahlung UKE Hirnmetastase"
74,nein,keine Therapie,05.07.2016,NA,,Dabrafenib/Trametinib,0,1.27,cutanes Melanom,trunk,m,39,nein,ja,2,2.9,3.4,241,0.04,pos.,,IV,"adj. Radiatio bis 06/14, 03-03/15 2 Gaben Ipilimumab (Abbruch),10.04.15 Beginn Tafinlar 150 mg 1-0-1, 26.04.15 Beginn Mekinist 2mg"
75,nein,Dez 15,04.08.2016,nein,,Dabrafenib/Trametinib,1,2.7 mm,cutanes Melanom,acral,w,66,ja,nein,3,1.3,4.6,211,0.12,pos.,,IV,"07/14 postop Radiatio,2/15 Dobrafenib 150 1-0-1 bis 12/15, Mekinist 2 mg 1-0-0 10/15 bis 12/15, 12/15-02/16 3 Zyklen Keytruda, 02/16 1Zyklus Yernoy, 03/16 1 Zyklus Temodal bis 05/16 3. Zyklus Temodal, 07/16 Dabrafenib 150 1-0-1 und Mekinist 2mg 1-0-0"
76,NA,Jan 17,04.08.2016,ja,++,-,0,4.2 mm,cutanes Melanom,extremities,m,,,,,8.8,1.2,201,0.03,neg.,,IV,
77,NA,keine Therapie,04.08.2016,NA,,Interferon alpha,0,2.0 mm,cutanes Melanom,extremities,m,43,nein,ja,1,1.6,0.9,189,0.02,pos.,,IIIA,"08/15 IFN pause, Re start 10/15 IFN 3x3 Mio Einheiten"
78,nein,Jul 16,11.08.2016,nein,,Ipilimumab+Nivolumab,1,1.1 mm,cutanes Melanom,trunk,w,,,,,7.3,1.2,250,0.57,NA,pos,IV,
79,ja,Aug 14,11.08.2016,nein,,Bis 02/16 Pembro mit complete response,1,1.0 mm,cutanes Melanom,trunk,w,75,nein,nein,3,0.4,7.7,214,0.07,pos.,,IV,"6/10-11/11 26ZyklenVencarafenib, 09/11-09/12 Zwei Zyklen Temodal, 2/12-4/12 Ipilimumab, 09/13-01/14 Taxol , 02/14 MEK Inhibitor, und Tafinlar 150 1-0-1, 03/14 Dabrafenib 75 1-0-1 und Tranetinib 1 1-0-0,4/14-2/16 26 Zyklen PD1, Radiatio 8/11"
80,nein,Sep 15,18.08.2016,nein,++,Dabrafenib/Trametinib,0,3.61 mm,cutanes Melanom,head / neck,w,31,ja,ja,2,2.3,4.5,188,0.06,pos.,,IV,"02/13-10/13IFN intermediate, 9/15 Keytruda-2Zyklen,10/15 Tafinlar 150-0-150,Mekinist 2mg, Radiatio 10/15, Dabrafenib, Tafinlar- Mekinist bis 01/17"
81,ja,Dez 15,23.08.2016,nein,,Pembrolizumab,0,1.95 mm,cutanes Melanom,extremities,w,57,ja,nein,2,5.9,0.6,169,0.04,pos.,,IV,"2/15 zellboraf 4x2, 12/15 zweimal Keytruda,03/16 Ganzhirnbestrahlung, 1/16- 9/17 insgesamt 25 Zyklen Keytruda"
82,nein,Okt 13,25.08.2016,nein,,Ipilimumab+Nivolumab,1,NA,Schleimhautmelanom,anal,w,,,,,4.3,47.2,2022,2.07,NA,pos,IV,
83,nein,Mai 16,30.08.2016,nein,,Nivolumab,1,0.78 mm,cutanes Melanom,extremities,m,,,,,0.2,21.6,235,5.41,pos.,,IV,
84,NA,keine Therapie,30.08.2016,NA,,Dabrafenib/Trametinib,0,1.27 mm,cutanes Melanom,trunk,m,38,nein,nein,3,3,3.8,210,0.07,pos.,,IV,"3/15 Ipilimumab 273mg und 4/15, 04/15 Tafinlar 150 1-0-1, 04/15 Moniris 2mg 1-0-0, seit 12/16 Tafinlar+Mekinist"
85,ja,Nov 16,30.08.2016,ja,,-,0,2.5 mm,cutanes Melanom,extremities,w,52,nein,ja,4,12.4,0.5,177,0.05,neg.,,IV,"11/16 Ipilimumab 3mg/kgKG und Nivolumab 1mgkgKG 4 zyklen, seit 2/17 Opdivo alle 2 Wochen 3mgKgkg, adjuvante IFN 06/13-07/14, Radiatio 08/14"
86,nein,Sep 16,15.09.2016,ja,,Pembrolizumab,0,14.0 mm,cutanes Melanom,trunk,w,49,nein,ja,1,4.1,8.8,195,0.3,pos.,,IV,"12/15-02/16 Radiatio postop Axilla, 02/16 Low dose IFN 3x3Mio, 03/16 Zellboraf, 09/16-10/16 3v Zyklen Pembrolizumab/Epacadostat Abbruch bei Progress, 12/16 Zellboraf 75 2-0-2"
87,NA,keine Therapie,27.10.2016,NA,,Dabrafenib/Trametinib,1,3.2 mm,cutanes Melanom,trunk,m,71,nein,,1,4.9,4.7,385,0.23,pos.,,IV,"keine Akte, nur MR Befund in Aktenmappe"
88,nein,Mai 16,27.10.2017,nein,,Vemurafenib + Cobimetinib,0,0.95 mm,cutanes Melanom,trunk,w,63,nein,nein,1,1.1,29.7,409,0.13,pos.,,IIIc,"05/2016-08/2106 4Zyklen Pembrolizumab 200, 09/2016Vemurafenib 2x400 Pause 10/2026 Restart Zellboraf 3-0-3 und Cobi 2-0-0 bis 01/2017 Restart 04/2017"
89,NA,keine Therapie,03.11.2016,NA,,-,0,2.1 mm,cutanes Melanom,head / neck,w,73,nein,nein,3,5.1,5.2,195,0.08,neg,,IV,2010- 4/2011 & zyklen DTIC Abbruch wegen kompletter Remission
90,ja,Dez 16,10.11.2016,ja,,-,0,9.2 mm,cutanes Melanom,trunk,m,76,,nein,1,5.4,1.7,183,0.94,pos.,,iV,12/2016-05/2017 8 Zyklen MSD252 Pembolizumab 200mg plus Epacadostat
91,nein,Nov 16,22.11.2016,ja,,Nivolumab,2,38.0 mm,cutanes Melanom,trunk,m,,,,,0.3,110.6,414,,neg.,,IV,
92,ja,Nov 16,22.11.2016,ja,,Pembrolizumab,0,5.6 mm,cutanes Melanom,head / neck,m,69,nein,nein,1,3.1,1.6,235,0.07,neg,,iV,11/2016- 372017 6zyklen Pembrolizumab 200mg+ Epacadostat 100
93,ja,Jun 16,24.11.2016,nein,,Nivolumab,0,1.0 mm,cutanes Melanom,trunk,m,,,,,0,1.3,194,0.05,pos.,,IV,
94,nein,Mai 16,24.11.2016,nein,,-,2,NA,cutanes Melanom,extremities,m,,,,,0.6,10.2,234,1.14,neg.,,IV,
95,ja,Nov 16,24.11.2016,ja,,Pembrolizumab,0,8.0 mm,cutanes Melanom,acral,m,76,nein,nein,2,2.6,6.1,173,0.24,neg.,,IV,"4Zyklen Pembro 200mg+Eparcardostat 11/16-1/17, $ Yervog 02/17-04/17 wegen Progress"
96,nein,Sep 17,29.11.2016,ja,,Ipilimumab+Nivolumab,1,NA,NA,NA,w,45,,nein,1,0.4,0.2,305,0.1,pos.,,IV,11/16 einmal Tefinlar 75 2-0-2 und Mekinest 2 1-0-0
97,nein,Nov 16,01.12.2016,ja,,Dabrafenib/Trametinib,1,NA,cutanes Melanom,trunk,w,,,,,6,2.4,161,0.23,pos.,,IV,
98,NA,Okt 17,01.12.2016,ja,,-,0,3.2 mm,cutanes Melanom,trunk,m,73,nein,nein,1,1.8,1.5,216,0.02,neg.,,Iib,12 Zyklen Pembrolizumab 9/16- 4/17
99,ja,Dez 16,07.12.2016,ja,,Pembrolizumab,1,7.0 mm,cutanes Melanom,trunk,m,78,nein,nein,3,2.7,6.6,296,0.1,pos.,,IV,9 zyklen Keytruda 2mg/kgKG 12/16-05/17
100,nein,Dez 16,07.12.2016,ja,,Ipilimumab+Nivolumab,1,0.7 mm,cutanes Melanom,trunk,m,52,,nein,1,0,0.5,277,1.09,neg.,,IV,3Zyklen Ipilimumab+ drei Zyklen Nivolumab 12/16-02/17
101,ja,Jan 17,10.01.2017,ja,,Ipilimumab+Nivolumab,0,3.25 mm,cutanes Melanom,head / neck,m,,,,,3.1,2.3,194,0.07,pos.,,,
102,nein,Jan 17,17.01.2017,ja,,Ipilimumab+Nivolumab,0,1.7 mm,cutanes Melanom,head / neck,m,51,ja,nein,4,2.6,80.8,569,3.64,pos.,,IV,1/17 1Zyklus Nivo116mg+Ipi 348mg. 1/17 Tafinlart und mekinest 150 1-0-1/2mg 1-0-0
103,ja,Okt 16,17.01.2017,nein,o,Pembrolizumab,2,3.2 mm,cutanes Melanom,acral,m,,nein,nein,2,0.4,11,248,0.1,neg.,,IV,10/16-lfd. Keytruda Z. n. 6 Zyklen
